161 related articles for article (PubMed ID: 8196081)
1. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
Schellens JH; Planting AS; van Acker BA; Loos WJ; de Boer-Dennert M; van der Burg ME; Koier I; Krediet RT; Stoter G; Verweij J
J Natl Cancer Inst; 1994 Jun; 86(12):906-12. PubMed ID: 8196081
[TBL] [Abstract][Full Text] [Related]
2. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
Verweij J; Aamdal S; Schellens J; Koier I; Lund B
Oncol Res; 1994; 6(10-11):519-23. PubMed ID: 7620220
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG).
Aamdal S; Lund B; Koier I; Houten M; Wanders J; Verweij J
Cancer Chemother Pharmacol; 2000; 45(1):85-8. PubMed ID: 10647507
[TBL] [Abstract][Full Text] [Related]
4. Gradient high-performance liquid chromatographic assay for the determination of the novel indoloquinone antitumour agent E09 in biological specimens.
Binger M; Workman P
J Chromatogr; 1990 Nov; 532(2):321-36. PubMed ID: 2084129
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
McLeod HL; Graham MA; Aamdal S; Setanoians A; Groot Y; Lund B
Eur J Cancer; 1996 Aug; 32A(9):1518-22. PubMed ID: 8911111
[TBL] [Abstract][Full Text] [Related]
6. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of EO9 anti-tumour activity by hydralazine.
Bibby MC; Sleigh NR; Loadman PM; Double JA
Eur J Cancer; 1993; 29A(7):1033-5. PubMed ID: 8499134
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
Graham MA; Senan S; Robin H; Eckhardt N; Lendrem D; Hincks J; Greenslade D; Rampling R; Kaye SB; von Roemeling R; Workman P
Cancer Chemother Pharmacol; 1997; 40(1):1-10. PubMed ID: 9137522
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
Schellens JH; Dombernowsky P; Cassidy J; Epelbaum R; Dirix L; Cox EH; Wanders J; Calabresi F; Paridaens R; Monfardini S; Wolff J; Loos WJ; Verweij J; Pavlidis N; Hanauske AR;
Anticancer Drugs; 2001 Aug; 12(7):583-90. PubMed ID: 11487714
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents.
Workman P; Binger M; Kooistra KL
Int J Radiat Oncol Biol Phys; 1992; 22(4):713-6. PubMed ID: 1544843
[TBL] [Abstract][Full Text] [Related]
11. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.
Dirix LY; Tonnesen F; Cassidy J; Epelbaum R; ten Bokkel Huinink WW; Pavlidis N; Sorio R; Gamucci T; Wolff I; Te Velde A; Lan J; Verweij J
Eur J Cancer; 1996 Oct; 32A(11):2019-22. PubMed ID: 8943690
[TBL] [Abstract][Full Text] [Related]
12. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
Smitskamp-Wilms E; Hendriks HR; Peters GJ
Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).
Pavlidis N; Hanauske AR; Gamucci T; Smyth J; Lehnert M; te Velde A; Lan J; Verweij J
Ann Oncol; 1996 Jul; 7(5):529-31. PubMed ID: 8839911
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
18. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.
Chung-Faye G; Palmer D; Anderson D; Clark J; Downes M; Baddeley J; Hussain S; Murray PI; Searle P; Seymour L; Harris PA; Ferry D; Kerr DJ
Clin Cancer Res; 2001 Sep; 7(9):2662-8. PubMed ID: 11555577
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
